Abstract
Orexins are excitatory neuropeptides that have a critical role in maintaining wakefulness. Orexin receptor antagonists promote sleep in animals and humans. Indeed, small molecule orexin receptor antagonists have demonstrated clinical proof-of-concept in the treatment of primary insomnia. This review describes optimization of orexin receptor antagonists across diverse structural classes with a focus on how molecules were designed to optimize potency, physicochemical properties, pharmacokinetics, brain penetration, and in vivo activity.
Keywords: Brain penetration, diazepane, g-protein coupled receptor, insomnia, neuropeptide, orexin, sleep, proof-of-concept, physicochemical properties, rapid eye movement (REM) sleep, prepro-orexin, sleep-wake cycle, DORA, cataplexy, high-throughput screen, dimethoxy-THIQ region
Current Topics in Medicinal Chemistry
Title: Discovery of Dual Orexin Receptor Antagonists (DORAs) for the Treatment of Insomnia
Volume: 11 Issue: 6
Author(s): Paul J. Coleman, Christopher D. Cox and Anthony J. Roecker
Affiliation:
Keywords: Brain penetration, diazepane, g-protein coupled receptor, insomnia, neuropeptide, orexin, sleep, proof-of-concept, physicochemical properties, rapid eye movement (REM) sleep, prepro-orexin, sleep-wake cycle, DORA, cataplexy, high-throughput screen, dimethoxy-THIQ region
Abstract: Orexins are excitatory neuropeptides that have a critical role in maintaining wakefulness. Orexin receptor antagonists promote sleep in animals and humans. Indeed, small molecule orexin receptor antagonists have demonstrated clinical proof-of-concept in the treatment of primary insomnia. This review describes optimization of orexin receptor antagonists across diverse structural classes with a focus on how molecules were designed to optimize potency, physicochemical properties, pharmacokinetics, brain penetration, and in vivo activity.
Export Options
About this article
Cite this article as:
J. Coleman Paul, D. Cox Christopher and J. Roecker Anthony, Discovery of Dual Orexin Receptor Antagonists (DORAs) for the Treatment of Insomnia, Current Topics in Medicinal Chemistry 2011; 11 (6) . https://dx.doi.org/10.2174/1568026611109060696
DOI https://dx.doi.org/10.2174/1568026611109060696 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of NUCB2/nesfatin-1 as a Possible Biomarker
Current Pharmaceutical Design Purine Molecules as Hypnogenic Factors Role of Adenosine, ATP, and Caffeine
Central Nervous System Agents in Medicinal Chemistry Is Type D Personality Here to Stay? Emerging Evidence Across Cardiovascular Disease Patient Groups
Current Cardiology Reviews Genetics of Anxiety Disorders - Status Quo and Quo Vadis
Current Pharmaceutical Design Lifestyle Changes and Surgical Treatment for Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Adiposity and the Gut - The Role of Gut Hormones
Current Nutrition & Food Science Possible Consequences of Blocking Transient Receptor Potential Vanilloid 1
Current Pharmaceutical Biotechnology Is Adult Hippocampal Neurogenesis Really Relevant for the Treatment of Psychiatric Disorders?
Current Neuropharmacology Use of Analogs of Peptide Hormones Conjugated to Cytotoxic Radicals for Chemotherapy Targeted to Receptors on Tumors
Current Drug Delivery Somatostatin and its Analogs
Current Drug Targets Protein-Energy Malnutrition Alters Hippocampal Plasticity-Associated Protein Expression following Global Ischemia in the Gerbil
Current Neurovascular Research From Protein to Peptides: a Spectrum of Non-Hydrolytic Functions of Acetylcholinesterase
Protein & Peptide Letters Neuroinflammation as a Common Mechanism Associated with the Modifiable Risk Factors for Alzheimer’s and Parkinson’s Diseases
Current Aging Science Effects of Interleukin 1β (IL-1β) and IL-1β/Interleukin 6 (IL-6) Combinations on Drug Metabolizing Enzymes in Human Hepatocyte Culture
Current Drug Metabolism Circadian MicroRNAs in Cardioprotection
Current Pharmaceutical Design The Crosstalk Between Insulin and Renin-Angiotensin-Aldosterone Signaling Systems and its Effect on Glucose Metabolism and Diabetes Prevention
Current Vascular Pharmacology Cannabinoid Hyperemesis Syndrome
Current Drug Abuse Reviews The Mechanism of Action of Salsolinol in Brain: Implications in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Biological Predictors of Aging and Potential of FTIR to Study Age-related Diseases and Aging Metabolic Fingerprint
Current Metabolomics Peptide Therapeutics in Neurodegenerative Disorders
Current Medicinal Chemistry